The FDA has approved Novartis' Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. Cosentyx, a fully human biologic that inhibits interleukin-17A, becomes the first and only anti-IL-17 biologic approved for the disease, and this is its 11th U.S. indication.
Polymyalgia rheumatica is a common inflammatory disease that primarily affects adults over 50, causing acute pain and stiffness in the shoulders, neck and hips. An estimated 966,000 people in the United States have the condition, and relapses affect up to 40% of patients in the first year. Steroids remain standard care, but long-term use increases the risk of osteoporosis, cardiovascular disease and diabetes.
Approval is based on REPLENISH, a global, randomized, double-blind, placebo-controlled Phase 3 trial conducted across 27 countries, in which patients received Cosentyx 300 mg, Cosentyx 150 mg or placebo, each combined with a 24-week steroid taper. The trial met its primary endpoint, with patients receiving Cosentyx 150 mg achieving sustained remission at week 52 at twice the rate of those on placebo: 40.5% versus 20.5%.
Serious adverse events occurred in 15.9% of the Cosentyx 150 mg group and 14.2% of the placebo group. Hypersensitivity reactions and urinary tract infections occurred more frequently with Cosentyx than placebo, and one fatal case of cryptococcal meningitis occurred in a treated patient.
The data were published in the New England Journal of Medicine and presented at the 2026 EULAR Congress. The PMR indication is already approved in the European Union, and Novartis has filed for review in Japan and other countries.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!